Kavita ici final master 1226 with diabetes
2025-12-26
read master
1year
| Characteristic | N = 1,3681 |
|---|---|
| Age | 72 (66, 79) |
| Gender_Legal_Sex | |
| Female | 525 (38%) |
| Male | 843 (62%) |
| male | |
| 0 | 525 (38%) |
| 1 | 843 (62%) |
| Race | |
| Asian | 53 (3.9%) |
| Black | 83 (6.1%) |
| Other/Unknown | 74 (5.4%) |
| White | 1,158 (85%) |
| Ethnic_Group | |
| Hispanic | 1,288 (94%) |
| Non_hispanic | 80 (5.8%) |
| ckd_incidence_1year | |
| 0 | 1,319 (96%) |
| 1 | 49 (3.6%) |
| ckd_progression_1year | |
| 0 | 1,090 (80%) |
| 1 | 278 (20%) |
| eskd_composite_1year | |
| 0 | 1,359 (99%) |
| 1 | 9 (0.7%) |
| ckd_composite_1year | |
| 0 | 1,040 (76%) |
| 1 | 328 (24%) |
| ckd_stage_1year | |
| 1 | 430 (31%) |
| 2 | 550 (40%) |
| 3 | 349 (26%) |
| 4 | 35 (2.6%) |
| 5 | 4 (0.3%) |
| ckd_stage_baseline | |
| 1 | 471 (34%) |
| 2 | 560 (41%) |
| 3 | 310 (23%) |
| 4 | 25 (1.8%) |
| 5 | 2 (0.1%) |
| dm | |
| 1 | 1,368 (100%) |
| htn | |
| 0 | 152 (11%) |
| 1 | 1,216 (89%) |
| cad | |
| 0 | 790 (58%) |
| 1 | 578 (42%) |
| ace_arb | |
| 0 | 335 (24%) |
| 1 | 1,033 (76%) |
| diu | |
| 0 | 386 (28%) |
| 1 | 982 (72%) |
| ppi | |
| 0 | 264 (19%) |
| 1 | 1,104 (81%) |
| steroids | |
| 0 | 217 (16%) |
| 1 | 1,151 (84%) |
| smoking | |
| 0 | 517 (38%) |
| 1 | 851 (62%) |
| Bevacizumab | |
| 0 | 1,278 (93%) |
| 1 | 90 (6.6%) |
| Cisplatin | |
| 0 | 1,189 (87%) |
| 1 | 179 (13%) |
| Carboplatin | |
| 0 | 898 (66%) |
| 1 | 470 (34%) |
| Pemetrexed | |
| 0 | 1,179 (86%) |
| 1 | 189 (14%) |
| Gemcitabine | |
| 0 | 1,189 (87%) |
| 1 | 179 (13%) |
| Cetuximab | |
| 0 | 1,331 (97%) |
| 1 | 37 (2.7%) |
| Trastuzumab | |
| 0 | 1,331 (97%) |
| 1 | 37 (2.7%) |
| VEGF_TKI | |
| 0 | 1,191 (87%) |
| 1 | 177 (13%) |
| pre_CRE_180days | 0.94 (0.75, 1.17) |
| pre_HGB_180days | 12.20 (10.80, 13.40) |
| Unknown | 7 |
| pre_ALB_180days | 4.00 (3.80, 4.30) |
| Unknown | 13 |
| eGFR_CRE_baseline | 79 (61, 95) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 8191 |
|---|---|
| Age | 73 (66, 79) |
| Gender_Legal_Sex | |
| Female | 318 (39%) |
| Male | 501 (61%) |
| male | |
| 0 | 318 (39%) |
| 1 | 501 (61%) |
| Race | |
| Asian | 28 (3.4%) |
| Black | 51 (6.2%) |
| Other/Unknown | 45 (5.5%) |
| White | 695 (85%) |
| Ethnic_Group | |
| Hispanic | 773 (94%) |
| Non_hispanic | 46 (5.6%) |
| ckd_incidence_2year | |
| 0 | 767 (94%) |
| 1 | 52 (6.3%) |
| ckd_progression_2year | |
| 0 | 635 (78%) |
| 1 | 184 (22%) |
| eskd_composite_2year | |
| 0 | 808 (99%) |
| 1 | 11 (1.3%) |
| ckd_composite_2year | |
| 0 | 581 (71%) |
| 1 | 238 (29%) |
| ckd_stage_1year | |
| 1 | 254 (31%) |
| 2 | 332 (41%) |
| 3 | 213 (26%) |
| 4 | 17 (2.1%) |
| 5 | 3 (0.4%) |
| ckd_stage_2year | |
| 1 | 245 (30%) |
| 2 | 339 (41%) |
| 3 | 205 (25%) |
| 4 | 25 (3.1%) |
| 5 | 5 (0.6%) |
| ckd_stage_baseline | |
| 1 | 280 (34%) |
| 2 | 341 (42%) |
| 3 | 181 (22%) |
| 4 | 15 (1.8%) |
| 5 | 2 (0.2%) |
| dm | |
| 1 | 819 (100%) |
| htn | |
| 0 | 89 (11%) |
| 1 | 730 (89%) |
| cad | |
| 0 | 488 (60%) |
| 1 | 331 (40%) |
| ace_arb | |
| 0 | 198 (24%) |
| 1 | 621 (76%) |
| diu | |
| 0 | 229 (28%) |
| 1 | 590 (72%) |
| ppi | |
| 0 | 154 (19%) |
| 1 | 665 (81%) |
| steroids | |
| 0 | 135 (16%) |
| 1 | 684 (84%) |
| smoking | |
| 0 | 312 (38%) |
| 1 | 507 (62%) |
| Bevacizumab | |
| 0 | 768 (94%) |
| 1 | 51 (6.2%) |
| Cisplatin | |
| 0 | 717 (88%) |
| 1 | 102 (12%) |
| Carboplatin | |
| 0 | 548 (67%) |
| 1 | 271 (33%) |
| Pemetrexed | |
| 0 | 707 (86%) |
| 1 | 112 (14%) |
| Gemcitabine | |
| 0 | 720 (88%) |
| 1 | 99 (12%) |
| Cetuximab | |
| 0 | 799 (98%) |
| 1 | 20 (2.4%) |
| Trastuzumab | |
| 0 | 797 (97%) |
| 1 | 22 (2.7%) |
| VEGF_TKI | |
| 0 | 712 (87%) |
| 1 | 107 (13%) |
| pre_CRE_180days | 0.95 (0.76, 1.18) |
| pre_HGB_180days | 12.40 (11.00, 13.60) |
| Unknown | 4 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 8 |
| eGFR_CRE_baseline | 80 (61, 94) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 4771 |
|---|---|
| Age | 73 (66, 80) |
| Gender_Legal_Sex | |
| Female | 187 (39%) |
| Male | 290 (61%) |
| male | |
| 0 | 187 (39%) |
| 1 | 290 (61%) |
| Race | |
| Asian | 17 (3.6%) |
| Black | 26 (5.5%) |
| Other/Unknown | 25 (5.2%) |
| White | 409 (86%) |
| Ethnic_Group | |
| Hispanic | 451 (95%) |
| Non_hispanic | 26 (5.5%) |
| ckd_incidence_3year | |
| 0 | 433 (91%) |
| 1 | 44 (9.2%) |
| ckd_progression_3year | |
| 0 | 372 (78%) |
| 1 | 105 (22%) |
| eskd_composite_3year | |
| 0 | 469 (98%) |
| 1 | 8 (1.7%) |
| ckd_composite_3year | |
| 0 | 325 (68%) |
| 1 | 152 (32%) |
| ckd_stage_1year | |
| 1 | 148 (31%) |
| 2 | 191 (40%) |
| 3 | 127 (27%) |
| 4 | 9 (1.9%) |
| 5 | 2 (0.4%) |
| ckd_stage_2year | |
| 1 | 145 (30%) |
| 2 | 199 (42%) |
| 3 | 121 (25%) |
| 4 | 11 (2.3%) |
| 5 | 1 (0.2%) |
| ckd_stage_3year | |
| 1 | 134 (28%) |
| 2 | 197 (41%) |
| 3 | 130 (27%) |
| 4 | 13 (2.7%) |
| 5 | 3 (0.6%) |
| ckd_stage_baseline | |
| 1 | 174 (36%) |
| 2 | 190 (40%) |
| 3 | 105 (22%) |
| 4 | 7 (1.5%) |
| 5 | 1 (0.2%) |
| dm | |
| 1 | 477 (100%) |
| htn | |
| 0 | 54 (11%) |
| 1 | 423 (89%) |
| cad | |
| 0 | 289 (61%) |
| 1 | 188 (39%) |
| ace_arb | |
| 0 | 108 (23%) |
| 1 | 369 (77%) |
| diu | |
| 0 | 136 (29%) |
| 1 | 341 (71%) |
| ppi | |
| 0 | 91 (19%) |
| 1 | 386 (81%) |
| steroids | |
| 0 | 79 (17%) |
| 1 | 398 (83%) |
| smoking | |
| 0 | 181 (38%) |
| 1 | 296 (62%) |
| Bevacizumab | |
| 0 | 453 (95%) |
| 1 | 24 (5.0%) |
| Cisplatin | |
| 0 | 422 (88%) |
| 1 | 55 (12%) |
| Carboplatin | |
| 0 | 329 (69%) |
| 1 | 148 (31%) |
| Pemetrexed | |
| 0 | 405 (85%) |
| 1 | 72 (15%) |
| Gemcitabine | |
| 0 | 422 (88%) |
| 1 | 55 (12%) |
| Cetuximab | |
| 0 | 464 (97%) |
| 1 | 13 (2.7%) |
| Trastuzumab | |
| 0 | 467 (98%) |
| 1 | 10 (2.1%) |
| VEGF_TKI | |
| 0 | 415 (87%) |
| 1 | 62 (13%) |
| pre_CRE_180days | 0.94 (0.76, 1.17) |
| pre_HGB_180days | 12.50 (11.10, 13.70) |
| Unknown | 3 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 4 |
| eGFR_CRE_baseline | 81 (62, 96) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 3031 |
|---|---|
| Age | 74 (67, 80) |
| Gender_Legal_Sex | |
| Female | 117 (39%) |
| Male | 186 (61%) |
| male | |
| 0 | 117 (39%) |
| 1 | 186 (61%) |
| Race | |
| Asian | 8 (2.6%) |
| Black | 12 (4.0%) |
| Other/Unknown | 18 (5.9%) |
| White | 265 (87%) |
| Ethnic_Group | |
| Hispanic | 283 (93%) |
| Non_hispanic | 20 (6.6%) |
| ckd_incidence_4year | |
| 0 | 275 (91%) |
| 1 | 28 (9.2%) |
| ckd_progression_4year | |
| 0 | 233 (77%) |
| 1 | 70 (23%) |
| eskd_composite_4year | |
| 0 | 298 (98%) |
| 1 | 5 (1.7%) |
| ckd_composite_4year | |
| 0 | 204 (67%) |
| 1 | 99 (33%) |
| ckd_stage_1year | |
| 1 | 92 (30%) |
| 2 | 122 (40%) |
| 3 | 80 (26%) |
| 4 | 8 (2.6%) |
| 5 | 1 (0.3%) |
| ckd_stage_2year | |
| 1 | 89 (29%) |
| 2 | 129 (43%) |
| 3 | 76 (25%) |
| 4 | 9 (3.0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 82 (27%) |
| 2 | 127 (42%) |
| 3 | 87 (29%) |
| 4 | 6 (2.0%) |
| 5 | 1 (0.3%) |
| ckd_stage_4year | |
| 1 | 87 (29%) |
| 2 | 123 (41%) |
| 3 | 86 (28%) |
| 4 | 6 (2.0%) |
| 5 | 1 (0.3%) |
| ckd_stage_baseline | |
| 1 | 104 (34%) |
| 2 | 124 (41%) |
| 3 | 70 (23%) |
| 4 | 5 (1.7%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 303 (100%) |
| htn | |
| 0 | 37 (12%) |
| 1 | 266 (88%) |
| cad | |
| 0 | 179 (59%) |
| 1 | 124 (41%) |
| ace_arb | |
| 0 | 58 (19%) |
| 1 | 245 (81%) |
| diu | |
| 0 | 79 (26%) |
| 1 | 224 (74%) |
| ppi | |
| 0 | 62 (20%) |
| 1 | 241 (80%) |
| steroids | |
| 0 | 55 (18%) |
| 1 | 248 (82%) |
| smoking | |
| 0 | 115 (38%) |
| 1 | 188 (62%) |
| Bevacizumab | |
| 0 | 290 (96%) |
| 1 | 13 (4.3%) |
| Cisplatin | |
| 0 | 272 (90%) |
| 1 | 31 (10%) |
| Carboplatin | |
| 0 | 220 (73%) |
| 1 | 83 (27%) |
| Pemetrexed | |
| 0 | 257 (85%) |
| 1 | 46 (15%) |
| Gemcitabine | |
| 0 | 272 (90%) |
| 1 | 31 (10%) |
| Cetuximab | |
| 0 | 298 (98%) |
| 1 | 5 (1.7%) |
| Trastuzumab | |
| 0 | 296 (98%) |
| 1 | 7 (2.3%) |
| VEGF_TKI | |
| 0 | 264 (87%) |
| 1 | 39 (13%) |
| pre_CRE_180days | 0.96 (0.78, 1.20) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| Unknown | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.40) |
| Unknown | 1 |
| eGFR_CRE_baseline | 79 (61, 95) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1871 |
|---|---|
| Age | 74 (66, 82) |
| Gender_Legal_Sex | |
| Female | 74 (40%) |
| Male | 113 (60%) |
| male | |
| 0 | 74 (40%) |
| 1 | 113 (60%) |
| Race | |
| Asian | 4 (2.1%) |
| Black | 10 (5.3%) |
| Other/Unknown | 13 (7.0%) |
| White | 160 (86%) |
| Ethnic_Group | |
| Hispanic | 172 (92%) |
| Non_hispanic | 15 (8.0%) |
| ckd_incidence_5year | |
| 0 | 164 (88%) |
| 1 | 23 (12%) |
| ckd_progression_5year | |
| 0 | 148 (79%) |
| 1 | 39 (21%) |
| eskd_composite_5year | |
| 0 | 183 (98%) |
| 1 | 4 (2.1%) |
| ckd_composite_5year | |
| 0 | 124 (66%) |
| 1 | 63 (34%) |
| ckd_stage_1year | |
| 1 | 55 (29%) |
| 2 | 78 (42%) |
| 3 | 50 (27%) |
| 4 | 3 (1.6%) |
| 5 | 1 (0.5%) |
| ckd_stage_2year | |
| 1 | 52 (28%) |
| 2 | 85 (45%) |
| 3 | 45 (24%) |
| 4 | 5 (2.7%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 48 (26%) |
| 2 | 88 (47%) |
| 3 | 48 (26%) |
| 4 | 2 (1.1%) |
| 5 | 1 (0.5%) |
| ckd_stage_4year | |
| 1 | 51 (27%) |
| 2 | 83 (44%) |
| 3 | 49 (26%) |
| 4 | 3 (1.6%) |
| 5 | 1 (0.5%) |
| ckd_stage_5year | |
| 1 | 45 (24%) |
| 2 | 91 (49%) |
| 3 | 43 (23%) |
| 4 | 7 (3.7%) |
| 5 | 1 (0.5%) |
| ckd_stage_baseline | |
| 1 | 65 (35%) |
| 2 | 79 (42%) |
| 3 | 39 (21%) |
| 4 | 4 (2.1%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 187 (100%) |
| htn | |
| 0 | 21 (11%) |
| 1 | 166 (89%) |
| cad | |
| 0 | 115 (61%) |
| 1 | 72 (39%) |
| ace_arb | |
| 0 | 36 (19%) |
| 1 | 151 (81%) |
| diu | |
| 0 | 45 (24%) |
| 1 | 142 (76%) |
| ppi | |
| 0 | 38 (20%) |
| 1 | 149 (80%) |
| steroids | |
| 0 | 37 (20%) |
| 1 | 150 (80%) |
| smoking | |
| 0 | 71 (38%) |
| 1 | 116 (62%) |
| Bevacizumab | |
| 0 | 179 (96%) |
| 1 | 8 (4.3%) |
| Cisplatin | |
| 0 | 168 (90%) |
| 1 | 19 (10%) |
| Carboplatin | |
| 0 | 135 (72%) |
| 1 | 52 (28%) |
| Pemetrexed | |
| 0 | 165 (88%) |
| 1 | 22 (12%) |
| Gemcitabine | |
| 0 | 167 (89%) |
| 1 | 20 (11%) |
| Cetuximab | |
| 0 | 185 (99%) |
| 1 | 2 (1.1%) |
| Trastuzumab | |
| 0 | 185 (99%) |
| 1 | 2 (1.1%) |
| VEGF_TKI | |
| 0 | 167 (89%) |
| 1 | 20 (11%) |
| pre_CRE_180days | 0.95 (0.75, 1.19) |
| pre_HGB_180days | 12.60 (11.20, 13.80) |
| Unknown | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 1 |
| eGFR_CRE_baseline | 79 (61, 96) |
| 1 Median (Q1, Q3); n (%) | |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
ckd_stage vs ckd_composite_5year
| 0 (N=124) |
1 (N=63) |
Overall (N=187) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 60 (48.4%) | 5 (7.9%) | 65 (34.8%) |
| stage 2 | 58 (46.8%) | 21 (33.3%) | 79 (42.2%) |
| stage 3 or more | 6 (4.8%) | 37 (58.7%) | 43 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 43 (34.7%) | 2 (3.2%) | 45 (24.1%) |
| stage 2 | 76 (61.3%) | 15 (23.8%) | 91 (48.7%) |
| Missing | 5 (4.0%) | 46 (73.0%) | 51 (27.3%) |
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| Age | 187 | 1.05 | 1.02, 1.09 | 0.002 |
| Gender_Legal_Sex | 187 | |||
| Female | — | — | ||
| Male | 1.10 | 0.59, 2.06 | 0.768 | |
| male | 187 | |||
| 0 | — | — | ||
| 1 | 1.10 | 0.59, 2.06 | 0.768 | |
| Ethnic_Group | 187 | |||
| Hispanic | — | — | ||
| Non_hispanic | 1.35 | 0.43, 3.92 | 0.591 | |
| htn | 187 | |||
| 0 | — | — | ||
| 1 | 1.72 | 0.64, 5.47 | 0.314 | |
| cad | 187 | |||
| 0 | — | — | ||
| 1 | 2.65 | 1.43, 4.99 | 0.002 | |
| ace_arb | 187 | |||
| 0 | — | — | ||
| 1 | 2.01 | 0.89, 4.99 | 0.110 | |
| diu | 187 | |||
| 0 | — | — | ||
| 1 | 3.53 | 1.56, 9.14 | 0.005 | |
| ppi | 187 | |||
| 0 | — | — | ||
| 1 | 1.83 | 0.83, 4.36 | 0.148 | |
| steroids | 187 | |||
| 0 | — | — | ||
| 1 | 0.45 | 0.22, 0.95 | 0.034 | |
| smoking | 187 | |||
| 0 | — | — | ||
| 1 | 0.99 | 0.53, 1.87 | 0.980 | |
| ckd_stage_baseline_3 | 187 | |||
| stage 1 | — | — | ||
| stage 2 | 4.34 | 1.64, 13.7 | 0.006 | |
| stage 3 or more | 74.0 | 23.1, 292 | <0.001 | |
| ckd_stage_5year_3 | 136 | |||
| stage 1 | — | — | ||
| stage 2 | 4.24 | 1.13, 27.7 | 0.063 | |
| Bevacizumab | 187 | |||
| 0 | — | — | ||
| 1 | 3.48 | 0.83, 17.4 | 0.096 | |
| Cisplatin | 187 | |||
| 0 | — | — | ||
| 1 | 0.68 | 0.21, 1.87 | 0.475 | |
| Carboplatin | 187 | |||
| 0 | — | — | ||
| 1 | 0.65 | 0.31, 1.29 | 0.226 | |
| Pemetrexed | 187 | |||
| 0 | — | — | ||
| 1 | 0.91 | 0.33, 2.29 | 0.843 | |
| Gemcitabine | 187 | |||
| 0 | — | — | ||
| 1 | 2.70 | 1.06, 7.09 | 0.038 | |
| Cetuximab | 187 | |||
| 0 | — | — | ||
| 1 | 1.98 | 0.08, 50.7 | 0.630 | |
| Trastuzumab | 187 | |||
| 0 | — | — | ||
| 1 | 1.98 | 0.08, 50.7 | 0.630 | |
| VEGF_TKI | 187 | |||
| 0 | — | — | ||
| 1 | 3.41 | 1.33, 9.19 | 0.012 | |
| pre_CRE_180days | 187 | 51.0 | 14.7, 213 | <0.001 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
cox model outcome: death
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| Age | 187 | 0.99 | 0.98, 1.01 | 0.268 |
| Gender_Legal_Sex | 187 | |||
| Female | — | — | ||
| Male | 0.85 | 0.64, 1.15 | 0.291 | |
| male | 187 | |||
| 0 | — | — | ||
| 1 | 0.85 | 0.64, 1.15 | 0.291 | |
| Ethnic_Group | 187 | |||
| Hispanic | — | — | ||
| Non_hispanic | 0.69 | 0.41, 1.18 | 0.176 | |
| htn | 187 | |||
| 0 | — | — | ||
| 1 | 0.79 | 0.50, 1.25 | 0.305 | |
| cad | 187 | |||
| 0 | — | — | ||
| 1 | 1.14 | 0.85, 1.53 | 0.385 | |
| ace_arb | 187 | |||
| 0 | — | — | ||
| 1 | 1.02 | 0.71, 1.47 | 0.926 | |
| diu | 187 | |||
| 0 | — | — | ||
| 1 | 1.13 | 0.81, 1.59 | 0.464 | |
| ppi | 187 | |||
| 0 | — | — | ||
| 1 | 1.02 | 0.71, 1.45 | 0.928 | |
| steroids | 187 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.80, 1.64 | 0.460 | |
| smoking | 187 | |||
| 0 | — | — | ||
| 1 | 1.00 | 0.74, 1.35 | 0.991 | |
| ckd_stage_baseline_3 | 187 | |||
| stage 1 | — | — | ||
| stage 2 | 1.01 | 0.73, 1.41 | 0.953 | |
| stage 3 or more | 0.86 | 0.59, 1.28 | 0.464 | |
| ckd_stage_5year_3 | 136 | |||
| stage 1 | — | — | ||
| stage 2 | 1.02 | 0.71, 1.45 | 0.933 | |
| Bevacizumab | 187 | |||
| 0 | — | — | ||
| 1 | 1.06 | 0.52, 2.17 | 0.864 | |
| Cisplatin | 187 | |||
| 0 | — | — | ||
| 1 | 1.25 | 0.78, 2.02 | 0.350 | |
| Carboplatin | 187 | |||
| 0 | — | — | ||
| 1 | 1.20 | 0.87, 1.65 | 0.271 | |
| Pemetrexed | 187 | |||
| 0 | — | — | ||
| 1 | 0.96 | 0.61, 1.49 | 0.848 | |
| Gemcitabine | 187 | |||
| 0 | — | — | ||
| 1 | 1.56 | 0.97, 2.49 | 0.065 | |
| Cetuximab | 187 | |||
| 0 | — | — | ||
| 1 | 2.02 | 0.50, 8.24 | 0.325 | |
| Trastuzumab | 187 | |||
| 0 | — | — | ||
| 1 | 0.44 | 0.11, 1.78 | 0.247 | |
| VEGF_TKI | 187 | |||
| 0 | — | — | ||
| 1 | 1.48 | 0.92, 2.35 | 0.103 | |
| pre_CRE_180days | 187 | 0.95 | 0.62, 1.44 | 0.794 |
| ckd_composite_5year | 187 | |||
| 0 | — | — | ||
| 1 | 0.92 | 0.68, 1.25 | 0.613 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||